Aim

The epidemic of COVID-19 has greatly affect the world health care system, particular measures have been taken not only to provide safety for health care providers but also to maintain the treatment quality. We evaluate the effect of COVID-19 epidemic to acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) received endovascular treatment (EVT) in our institution.

Methods

AIS patients with LVO who underwent EVT in the period of January 1st to April 30th between 2015 and 2020 from our stroke center. The baseline characteristics, working flow time, safety and efficacy outcome and the hospitalization status were retrospectively reviewed, compared and analyzed.

Results

There is significant decline in the number of AIS patients with LVO treated compared with the previous year (36 Vs 72 patients) during the epidemic period. The door to puncture time was significantly prolong (225 minutes versus 115 minutes) as well as the length of hospital stay with increase of the hospitalization costs (P < 0.05 for all). There is no significant difference on the safety and efficacy outcome, such recanalization rate, incidence of intracranial hemorrhage, functional independence and mortality during the epidemic (P > 0.05 for all).

Conclusions

Prolongation of the working time flow during the COVID-19 epidemic did not influence the safety and efficacy of EVT in AIS patients with LVO. However, special policy and particular measures in this circumstances is still need to evolve to improve the treatment quality.

中文翻译：

---

2019冠状病毒病（COVID-19）对大血管闭塞急性缺血性卒中机械取栓的工作流程、安全性和疗效结果的影响

目的

COVID-19 的流行极大地影响了世界卫生保健系统，已采取特别措施不仅为卫生保健提供者提供安全，而且还保持治疗质量。我们评估了 COVID-19 流行对我们机构接受血管内治疗 (EVT) 的大血管闭塞 (LVO) 急性缺血性卒中 (AIS) 患者的影响。

方法

2015 年至 2020 年 1 月 1 日至 4 月 30 日期间在我院卒中中心接受 EVT 的 AIS 伴 LVO 患者。对基线特征、工作流程时间、安全性和有效性结果以及住院情况进行回顾性分析、比较和分析。

结果

疫情期间接受LVO治疗的AIS患者数量较上年（36人比72人）明显下降。穿刺时间显着延长（225 分钟对 115 分钟）以及住院时间随着住院费用的增加而增加（均P  < 0.05）。疫情期间再通率、颅内出血发生率、功能独立性和死亡率等安全性和有效性结局均无显着差异（均P  >0.05）。

结论

在 COVID-19 流行期间延长工作时间不会影响 EVT 在 AIS 合并 LVO 患者中的安全性和有效性。但是，在这种情况下，还需要制定特殊的政策和具体措施，以提高治疗质量。